MOR.DE - MorphoSys AG
| Previous Close | 99.50 |
| Open | 99.40 |
| Bid | 100.60 x 1500 |
| Ask | 100.70 x 8800 |
| Day's Range | 99.10 - 101.20 |
| 52 Week Range | 76.45 - 124.90 |
| Volume | 41,636 |
| Avg. Volume | 137,121 |
| Market Cap | 3.178B |
| Beta (3Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.86 |
| Earnings Date | Aug 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.55 |
- ACCESSWIRE•11 days ago
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
NASDAQ: MOR) and Vivoryon Therapeutics AG (VVY) today announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. In exchange, MorphoSys has committed to investing up to EUR 15 million in a minority stake in Vivoryon Therapeutics as part of a capital raise planned for later this year.
- ACCESSWIRE•16 days ago
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 3, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that its licensing partner GSK reported in a press ...
- ACCESSWIRE•16 days ago
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 3, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that its licensing partner GSK reported in a press ...
- ACCESSWIRE•24 days ago
CORRECTION: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
Correction of a release disseminated on June 24, 2019. Correction of an inside information acc. to Article 17 MAR of the Regulation (EU). This release clarifies Dr. Kress's years of experience. PLANEGG ...
- ACCESSWIRE•25 days ago
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul ...
- Reuters•25 days ago
UPDATE 2-European shares fall as Daimler weighs, Sino-U.S. trade news awaited
Weak German economic data and a profit warning from Daimler weakened European stock markets on Monday as investors reined in any bets on a fourth week of gains before G20 meetings that may see more trade talks between the U.S. and Chinese presidents. The main European index has shown signs of flagging in the past week after recouping almost all of its losses from a sharp sell-off in May, helped by expectations of more monetary stimulus globally. Corporate newsflow continues to point to a slowdown in growth and Mercedes-Benz maker Daimler dropped 3.8% after it cut its 2019 earnings outlook and lifted provisions for issues related to its diesel vehicles by hundreds of millions of euros.
- ACCESSWIRE•27 days ago
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
The L-MIND study enrolled patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), who are ineligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The primary analysis data reported today included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year.
- ACCESSWIRE•last month
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced today that its licensee Janssen Research & Development, ...
- ACCESSWIRE•2 months ago
MorphoSys to Present at Upcoming Investor Conferences
PLANEGG, MUNICH, GERMANY / ACCESSWIRE / May 23, 2019 / MorphoSys AG ( FSE: MOR ; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR ) will present at the following conferences: Jefferies Healthcare Conference ...
- ACCESSWIRE•2 months ago
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 16, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced results from the primary analysis (cut-off date November ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of MOR.DE earnings conference call or presentation 8-May-19 12:00pm GMT
Q1 2019 Morphosys AG Earnings Call
Motley Fool•2 months agoMorphoSys AG (MOR) Q1 2019 Earnings Call Transcript
MOR earnings call for the period ending March 31, 2019.
- ACCESSWIRE•2 months ago
MorphoSys AG Reports First Quarter 2019 Results
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. ...
- ACCESSWIRE•3 months ago
Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 2, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first three months' 2019 results on May 7, 2019 at 10:00pm ...
- ACCESSWIRE•3 months ago
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. "The initiation of our first phase 3 trial represents another important milestone in advancing MOR202/TJ202 towards registration with the hope of providing more therapeutic options for multiple myeloma patients globally. Under I-Mab's fast-to-market development strategy, the phase 3 study, if successful, could lead to a biologics license application (BLA) in Greater China.
- ACCESSWIRE•3 months ago
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / April 23, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR), Galapagos NV (Euronext & NASDAQ: GLPG) and Novartis Pharma ...
- Benzinga•3 months ago
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
- ACCESSWIRE•3 months ago
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 15, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC ...
- ACCESSWIRE•3 months ago
MorphoSys Nominates New Candidate for Supervisory Board
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company's ordinary ...
- ACCESSWIRE•4 months ago
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
Sarah joins MorphoSys from Qiagen N.V., a leading global provider of sample and assay technologies for molecular diagnostics, academic research, the pharmaceutical industry and applied testing. Qiagen is listed in the German indexes MDAX and TecDAX as well as at the New York Stock Exchange. Sarah has held the position of Director Investor Relations since April 2018 at Qiagen N.V. in Hilden.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of MOR.DE earnings conference call or presentation 14-Mar-19 1:00pm GMT
Full Year 2018 Morphosys AG Earnings Call
- ACCESSWIRE•4 months ago
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.
- ACCESSWIRE•4 months ago
MorphoSys Presents Results for Fiscal Year 2018
Conference call and webcast (in English) tomorrow, March 14, 2019 at 2:00pm CET (1:00pm GMT/9:00am EDT) Highlights in R&D and corporate development - Interim data from all patients enrolled in ongoing ...